期刊文献+

血清IL-2水平对胸水TIL细胞体外扩增及活性的影响 被引量:1

The influence of the level of serum IL-2 on the proliferation rate and anti-tumor activity of the tumor-infiltrating lymphocytes derived from malignant pleural fluid in vitro
下载PDF
导出
摘要 目的 通过对血清白介素 2 (interleukine 2 ,IL 2 )水平的检测 ,了解内源性IL 2水平对胸水TIL细胞体外扩增及抗肿瘤活性的影响。方法 对 5 4例有恶性胸水患者 ,第一次抽胸水时无菌收集胸水 ,进行TIL细胞培养 ,并同时进行血清IL 2水平检测。TIL细胞体外杀瘤活性用MTT法检测 ,血清IL 2的水平用ELISA法检测。将IL 2水平较高的 2 7例患者分为 1组 ,IL 2水平较低的 2 7例患者分为另 1组 ,比较两组患者胸水TIL细胞体外增殖速度及杀瘤活性。结果 血清IL 2水平较低组 ,TIL细胞体外培养 8天后扩增 5 9.3± 2 0 .9倍 ,培养 12天后扩增 112 .5± 32 .9倍 ,明显高于IL 2水平较高组的 2 4 .0± 11.0倍和 6 2 .5± 2 1.9倍。IL 2水平较低组TIL细胞体外杀瘤率为 4 5 .3± 9.5 % ,明显高于IL 2水平较高组的 2 6 .7± 7.3% ,P<0 .0 5。结论 血清IL 2水平高低与TIL细胞体外增殖的速度及其杀瘤活性明显相关 ,IL 2水平较低的患者胸水中TIL细胞体外增殖的速度较快 ,杀瘤活性较强。血清IL 2水平可望作为恶性胸水IL 2 /TIL治疗选择的指标。 Objective To explore the influence of serum IL-2 level on the proliferation rate and anti-tumor activity of the tumor-infiltrating lymphocytes (TIL) derived from malignant pleural fluid in vitro. Methods Fifty four patients with malignant pleural fluid were studied. The level of serum IL-2 was measured by ELISA. TILs were purified from malignant pleural fluid of these patients and cultured in the presence of IL-2. MTT assay was used to detect the cytotoxicity against Lovo cell line of TILs in 2 groups (one guroup IL-2>27,amd the other IL-2<27).Results The proliferation rate of TIL in the group with lower level of IL-2 was 59.3±20.9 after 8 days incubation and 112.5±32.9 after 12 days which was higher than those of group with higher IL-2 level. The cytotoxicity against Lovo cell lines at the group with lower level of IL-2 was stronger than that of group with higher IL-2 level( P <0.05).Conclusion The level of serum IL-2 is relate to the proliferation rate and cytotoxicity against Lovo cell line of the TILs derived from the malignant pleural fluid.
出处 《肿瘤》 CAS CSCD 北大核心 2004年第2期182-183,共2页 Tumor
关键词 血清 胸水 TIL细胞 体外扩增 白细胞介素-2 恶性肿瘤 Pleural effusion,malignant Interleukin-2 Lymphocytes,tumor-infiltrating
  • 相关文献

参考文献2

  • 1Freedman RS, Edwards CL, Kavanagh JJ, et al. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial[J]. J Immunother Emphasis Tumor Immunol, 1994,16(3):198
  • 2方正,门奋勇,李海金,郑曼静,张学谦.白细胞介素-2浆膜腔内注射治疗恶性积液[J].中国肿瘤临床,1997,24(5):390-391. 被引量:15

共引文献15

同被引文献15

  • 1朱铁年,赵瑞景,周学敏,刘文虎,孔月,孙志学.胎脾LAK细胞联合rlL-2治疗癌性胸水临床观察[J].中国肿瘤临床,1995,22(5):325-327. 被引量:3
  • 2Foa R, Guarim A, Gansbacher B. IL -2 treatment for cancer: from biology to therapy[J]. Br J Cancer, 1992,66(4) : 992.
  • 3Maas RA, Dulleus HFJ, Otter WD. Interleukin -2 in cancer treatment : disappointing or (still) promoising? a review[ J ]. Cancer Immunol Immunother ,1993,36(2) :141.
  • 4Astoul P, Viallat J R, Laurent J C, et al. Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion[ J].Chest, 1993,103 ( 1 ) : 209.
  • 5Rosenherg SA. A progress report on the treatment of 157 patients with advanced cancer using LAK cellsand rIL - 2 or high - dose of IL-2 alone[J]. V Engl J Med,1987,316(4):889.
  • 6Pizza G, V iza D, Vinci CD, et all. Intra -lymphatic adm instration of interleukin - 2 ( IL - 2 ) in cancer patients : a pilot study[J]. LymphokineRes, 1988,7(1):45.
  • 7Vaage J. Local interleukin -2 therapy ofmouse mammary tumors of various immunogenicities [ J ]. Cancer Res, 1988,48 ( 11 ) : 2193.
  • 8Yasumoto K, Mivazaki K, Nagashima A, et aL Induction of lymphokine - activated killer cells by intrapleural instillations of recombinant interleukin -2 in patients with malignant pleurisy due to lung cancer[ J]. Cancer Res, 1987,47(8) : 2184.
  • 9Ratto G B, Melioli G, Zino P, et al. Immunotherapy with the use of tumor - infiltrating lymphocytes and interleukin - 2 as adjuvant treatment in stage Ⅲ non - small - cell lung cancer. A pilot study[J]. J Thorac Cardiovasc Surg,1995,109(6) : 1212.
  • 10程爱明,李金陵,梁克理,刘风枝.重组白介素-2治疗癌性胸腔积液疗效及NK细胞活性观察[J].中国肿瘤临床,1997,24(10):781-782. 被引量:2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部